Isosorbide Mononitrate

Summary

Isosorbide Mononitrate (CHEMBL1311) is an approved small-molecule vasodilator agent (ATC C01DA14); indicated across 11 conditions including cardiovascular disorder and coronary artery disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01DA14
• Indications: 11 conditions
• Clinical trials: 31
• Chemistry: 191.14 Da · C6H9NO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1311
Name	Isosorbide Mononitrate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	27661
ChEBI	CHEBI:6062
ATC	C01DA14
Molecular formula	C6H9NO6
Molecular weight	191.14
InChIKey	YWXYYJSYQOXTPL-SLPGGIOYSA-N

SMILES: C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])O

IUPAC name: [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate

Pharmacological roles (ChEBI): nitric oxide donor, vasodilator agent.

Also known as: AHR-4698, Angeze 10, Angeze 20, Angeze 40, Angeze sr 40, Angeze sr 60, Angitate, Astrodur mr, BM 22.145, BM-22.145, BM-22145, Carmil xl

Patent coverage: 12,003 distinct patent families (34,192 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
coronary artery disorder	4	MONDO:0005010	EFO:0001645

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hypertensive disorder	2	MONDO:0005044	EFO:0000537
heart failure	2	MONDO:0005252	EFO:0003144
stroke disorder	2	MONDO:0005098	EFO:0000712
oligohydramnios	2	MONDO:0005881	EFO:0007401
vascular disorder	1	MONDO:0005385	EFO:0004264

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 31.

Phase distribution

Phase	Trials
PHASE2	7
PHASE4	6
Not specified	6
PHASE3	5
PHASE1	3
EARLY_PHASE1	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00450164	PHASE4	COMPLETED	Secondary Prophylaxis After Variceal Bleeding in Non-Responders
NCT02011620	PHASE4	WITHDRAWN	Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03407521	PHASE4	COMPLETED	Misoprosotol and Isosorbide Mononitrate for Induction of Second Trimester Abortion
NCT03544606	PHASE4	COMPLETED	Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor
NCT06730945	PHASE4	WITHDRAWN	Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After CABG
NCT07252544	PHASE3	NOT_YET_RECRUITING	Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)
NCT02152579	PHASE3	UNKNOWN	Efficacy and Safety of Monocordil Manufactured by Laboratórios Baldacci
NCT02712125	PHASE2/PHASE3	COMPLETED	Nitric Oxide Donors for Treatment of Isolated Oligohydramnios
NCT03665779	PHASE3	COMPLETED	Nitric Oxide Donor Isosorbide Mono Nitrate for Induction of Labor With Pre-labor Rupture of Membranes
NCT04311658	PHASE3	UNKNOWN	Safety and Efficacy of the Effect of Isosorbide Mononitrate in Reducing Pain During Levonorgestrel-releasing Intrauterine Device Insertion
NCT04312048	PHASE3	COMPLETED	the Effect of Isosorbide Mononitrate in Reducing Pain During Cooper Intrauterine Device Insertion
NCT07456852	PHASE1/PHASE2	NOT_YET_RECRUITING	Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
NCT01961453	PHASE2	WITHDRAWN	Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function
NCT02053493	PHASE2	COMPLETED	Nitrate’s Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction
NCT02481323	PHASE2	COMPLETED	Lacunar Intervention Trial 1 (LACI-1)
NCT02573051	PHASE2	WITHDRAWN	Termination Of Anembryonic Pregnancy
NCT02738177	PHASE2	UNKNOWN	Misoprostol Versus Effox as Cervical Ripening Agent Prior Surgical Evacuation
NCT03854383	PHASE2	UNKNOWN	Using Isosorbide Mononitrate in Reducing Time in Induction of Labor in Post Date Women
NCT04051957	PHASE2	TERMINATED	Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
NCT02667535	PHASE1	WITHDRAWN	PK, PD and Safety Comparative Trial of Isosorbide Mononitrate Gel in Healthy Participants and With Anal Fissure
NCT03557580	PHASE1	COMPLETED	A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects
NCT04729088	PHASE1	WITHDRAWN	Pharmacokinetics Trial of Isosorbide Mononitrate 0.5% Gel for Intra Anal Application in Healthy Subjects
NCT04482881	EARLY_PHASE1	UNKNOWN	Isosorbide Mononitrate in Induction of Labour
NCT05341856	EARLY_PHASE1	UNKNOWN	Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL
NCT06715007	Not specified	RECRUITING	Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
NCT07121634	Not specified	ACTIVE_NOT_RECRUITING	Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial
NCT00168519	Not specified	COMPLETED	Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes
NCT01631409	Not specified	WITHDRAWN	Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy
NCT03587077	Not specified	UNKNOWN	Pain Relief During IUD Insertion in Women Delivered Only by Elective Cesarean Section
NCT04217668	Not specified	COMPLETED	Headache Provocation of People Who Are Unable to Have Headache

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).